{"id":1068520,"date":"2024-05-06T02:42:49","date_gmt":"2024-05-06T06:42:49","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/tar-200-monotherapy-shows-greater-than-80-percent-complete-response-rate-in-patients-with-high-risk-non-muscle-invasive-bladder-cancer\/"},"modified":"2024-08-18T11:48:17","modified_gmt":"2024-08-18T15:48:17","slug":"tar-200-monotherapy-shows-greater-than-80-percent-complete-response-rate-in-patients-with-high-risk-non-muscle-invasive-bladder-cancer","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/tar-200-monotherapy-shows-greater-than-80-percent-complete-response-rate-in-patients-with-high-risk-non-muscle-invasive-bladder-cancer.php","title":{"rendered":"TAR-200 monotherapy shows greater than 80 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer"},"content":{"rendered":"<p><![CDATA[New data from Phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98 percent achieving a CR within 12 weeks1]]><\/p>\n<p>Here is the original post:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/05\/03\/2875260\/0\/en\/TAR-200-monotherapy-shows-greater-than-80-percent-complete-response-rate-in-patients-with-high-risk-non-muscle-invasive-bladder-cancer.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"TAR-200 monotherapy shows greater than 80 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer\">TAR-200 monotherapy shows greater than 80 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Here is the original post: TAR-200 monotherapy shows greater than 80 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/tar-200-monotherapy-shows-greater-than-80-percent-complete-response-rate-in-patients-with-high-risk-non-muscle-invasive-bladder-cancer.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068520","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068520"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068520"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068520\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}